Abstract
This Practice Point commentary discusses the findings and limitations of a randomized, double-blind study conducted by Parving and colleagues. The study evaluated the renoprotective effects of dual blockade of the renin–angiotensin–aldosterone system by adding aliskiren (an oral, direct renin inhibitor) or placebo to treatment with 100 mg daily losartan in patients who had hypertension and type 2 diabetes with nephropathy. Addition of daily aliskiren for 6 months (150 mg/day for 3 months and 300 mg/day for 3 months) reduced the mean urinary albumin:creatinine ratio by 20% (P <0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren versus only 12.5% of those who received placebo (P <0.001). At study end, mean blood pressure levels were only slightly lower in the aliskiren group than in the placebo group (2/1 mmHg lower). The authors concluded that aliskiren might have renoprotective effects that are independent of its blood-pressure-lowering effect in patients who have hypertension, type 2 diabetes and nephropathy and are receiving the recommended renoprotective treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schernthaner G (2008) Kidney disease in diabetology: lessons from 2007. Nephrol Dial Transplant 23: 1112–1115
Parving HH et al. (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358: 2433–2446
Oparil S et al. (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370: 221–229
Persson F et al. (2008) Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73: 1419–1425
ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560–2572
Mogensen CE et al. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 321: 1440–1444
Bakris GL et al. (2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72: 879–885
ONTARGET Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547–1559
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Schernthaner, G. Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. Nat Rev Nephrol 4, 656–657 (2008). https://doi.org/10.1038/ncpneph0962
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0962
This article is cited by
-
Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats
Naunyn-Schmiedeberg's Archives of Pharmacology (2016)